Bio & Pharma
Ybrain, Chong Kun Dang join forces for digital medicine distribution
Chong Kun Dang will have exclusive supply rights and sell Mindd Stim to S.Korean psychiatrists
By Jan 31, 2023 (Gmt+09:00)
1
Min read
Most Read
Samsung steps up AR race with advanced microdisplay for smart glasses


When in S. Korea, it’s a ritual: Foreigners make stops at CU, GS25, 7-Eleven


Maybe Happy Ending: A robot love story that rewrote Broadway playbook


NPS yet to schedule external manager selection; PE firms’ fundraising woes deepen


US auto parts tariffs take effect; Korea avoids heavy hit



South Korean electroceutical platform company Ybrain Inc. said on Tuesday it has entered into a joint promotion agreement with Chong Kun Dang Pharmaceutical Corp. for the distribution of its bioelectronic medicine device Mindd Stim.
The device is used to treat symptoms of depression through electrical stimulation.
Under the terms of the agreement, Chong Kun Dang will have exclusive supply rights and sell the product to domestic psychiatrists, while Ybrain will handle product installation and customer inquiries.
"Our goal for 2023 is to become a globally competitive leader in digital medicine and customized medicines," said Kim Young-joo, CEO of Chong Kun Dang.
"With this agreement in place, we aim to diagnose depression earlier and create a more favorable treatment environment in Korea," said Lee Ki-won, CEO of Ybrain.
Write to Yoorim Kim at youforest@hankyung.com
More to Read
-
Bio & PharmaDaewoong Pharma, Neurolive to jointly develop new antidepressant drug
Dec 28, 2022 (Gmt+09:00)
1 Min read -
Korean startupsMental health app Spring Health emerges amid pandemic
Nov 29, 2021 (Gmt+09:00)
3 Min read
Comment 0
LOG IN